Breaking News

WuXi PharmaTech Begins HPAPI Ops

May 28, 2014

Adds HPAPI processing capabilities at Shanghai lab

WuXi PharmaTech’s manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operations for a high-potency active pharmaceutical ingredient (HPAPI) at its lab in Shanghai. The lab has added HPAPI processing to its portfolio of services to support process development and clinical trial supply of high-potency small molecules at kilogram scale.
"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.

blog comments powered by Disqus